Is Ozempic Safe While Breastfeeding? What Nursing Mothers Need to Know

The short answer: Ozempic is not recommended while breastfeeding

The FDA-approved prescribing information for Ozempic states that there are no data on the presence of semaglutide in human milk, its effects on the breastfed infant, or its effects on milk production. The label concludes that the developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need for the drug and any potential adverse effects on the infant.

That language sounds measured, but what it means in practice is this: because we have no human data, clinicians cannot reassure you that semaglutide is safe for your baby. Most women's-health providers will advise stopping Ozempic before you begin breastfeeding or choosing not to start it while you are nursing.

This article walks through exactly what the science does and does not tell us, what happens to your weight-loss or diabetes goals while you are breastfeeding, and what options are actually available to you at this life stage.

What Ozempic is and why postpartum women ask about it

Ozempic is a once-weekly injectable GLP-1 receptor agonist approved by the FDA in 2017 for type 2 diabetes (T2D) in adults. Its active ingredient, semaglutide, is also sold as Wegovy (2.4 mg weekly) specifically for chronic weight management. Off-label prescribing of Ozempic 0.5 mg to 2.0 mg for weight loss has become common, and postpartum women are among those asking whether they can use it while still nursing.

Why postpartum women consider it

Postpartum weight retention is a real and under-discussed clinical problem. Roughly 75% of women weigh more one year after delivery than they did before pregnancy, and about 47% retain at least 5 kg above their pre-pregnancy weight. For women with PCOS, gestational diabetes, or pre-existing obesity, that retention compounds long-term metabolic risk. It is no surprise that a drug showing 10 to 15% body-weight reduction in trials like SUSTAIN-6 and STEP 1 would appeal to a new mother struggling with postpartum weight.

Who is most likely to consider Ozempic postpartum

• Women with T2D who were on semaglutide before pregnancy and want to restart
• Women with PCOS who used semaglutide off-label for insulin resistance or weight
• Women with obesity who lost access to structured weight programs during pregnancy
• Women who saw rapid weight gain in the third trimester and want to address it quickly

Each of these groups faces different risk-benefit math. None of them currently have human lactation data to guide the decision.

What the science actually shows about semaglutide in breast milk

Human data: none

As of mid-2025, no published peer-reviewed study has measured semaglutide concentrations in human breast milk. The National Institutes of Health LactMed database entry for semaglutide confirms that no published data exist on the excretion of semaglutide into human milk. This is not a case where the data exist but are reassuring. The data simply do not exist.

That absence matters. Without milk-concentration data, we cannot calculate a relative infant dose (RID), which is the standard pharmacokinetic tool used to assess whether a drug is compatible with breastfeeding. A RID below 10% is conventionally considered low-risk. For semaglutide, no RID can be computed.

Animal data: present but limited

The FDA label notes that semaglutide was detected in the milk of lactating rats. Rat pup plasma concentrations were approximately 3 to 13% of maternal plasma concentrations, suggesting some transfer does occur. Rat mammary physiology differs meaningfully from human mammary physiology, so this finding cannot be directly applied to humans. Still, the fact that transfer occurs in an animal model means dismissing the concern entirely would be premature.

Why semaglutide's molecular size is not fully reassuring

GLP-1 receptor agonists are large peptide molecules. Larger molecules generally transfer into breast milk in smaller amounts than small lipophilic drugs. Some clinicians have used this reasoning to suggest semaglutide transfer might be minimal. This is a reasonable hypothesis, but it remains extrapolation. Insulin, for example, is also a large peptide, and studies confirm that some insulin does appear in human milk, though it is largely degraded in the infant's GI tract. Whether semaglutide behaves similarly or differently is unknown.

Potential infant risks if exposure does occur

If semaglutide does pass into milk in meaningful amounts, the theoretical concerns for a nursing infant include:

• GI effects: GLP-1 receptors are present throughout the infant gut. Semaglutide-mediated slowing of gastric emptying could theoretically affect feeding behavior and growth.
• Hypoglycemia: GLP-1 receptor agonists in adults carry a low risk of hypoglycemia on their own, but an infant's glucose regulation is less mature.
• Growth disruption: Animal studies show that early-life GLP-1 signaling plays a role in pancreatic beta-cell development. Whether exogenous GLP-1 agonism in a nursing infant could alter this development is not known.

None of these risks are confirmed in humans. They are theoretical. But theoretical risks in a newborn or infant, in the absence of any offsetting evidence of safety, are taken seriously.

What the FDA label and major guidelines say

FDA prescribing information

The Ozempic label places the drug in the category of drugs for which data are insufficient to determine risk. The label does not say the drug is contraindicated in lactation. It says the decision should weigh the benefit of breastfeeding against the mother's need for the drug and possible infant risk. In practical clinical terms, this framing places the burden on the prescriber to justify continued use, not to justify stopping.

ACOG guidance on postpartum weight management

ACOG's 2021 Committee Opinion on Obesity in Pregnancy advises that postpartum weight management counseling should include behavioral interventions as first-line approaches, with pharmacotherapy reserved for specific clinical indications. ACOG does not endorse routine postpartum GLP-1 agonist use, particularly during lactation, given the absence of safety data. Any pharmacotherapy decision postpartum should be individualized and guided by a clinician familiar with lactation pharmacology.

The Menopause Society and postpartum context

Although the postpartum period is not menopause, the overlap between postpartum hormonal shifts and metabolic health is clinically meaningful. The Menopause Society has noted the importance of managing weight across all hormonal life stages, but its 2023 position statement on menopause and obesity does not address GLP-1 use during lactation. The gap in guideline coverage here mirrors the evidence gap.

The WomanRx Lactation Decision Framework for Ozempic:

Clinicians at WomanRx use a four-question framework when a postpartum patient raises Ozempic during a lactation-active period.

1. Is this drug being used for T2D, or for weight loss alone?
2. Can the clinical goal (glycemic control or weight management) be met with a lactation-compatible alternative for the duration of nursing?
3. How long does the patient plan to breastfeed, and what is the clinical urgency of resuming semaglutide?
4. Has the patient been counseled on how stopping breastfeeding to use semaglutide compares to continuing breastfeeding with alternative management?

This framework does not produce an automatic answer, but it structures the conversation so that the decision is genuinely informed rather than driven by assumption in either direction.

Pregnancy and lactation safety: the complete picture

Pregnancy category and human data

Semaglutide is contraindicated in pregnancy. The FDA label states that based on animal data, Ozempic may cause fetal harm when administered to a pregnant woman. Animal studies showed skeletal abnormalities, reduced fetal weight, and increased fetal mortality at doses below those used in humans. No adequate, well-controlled trials in pregnant women have been conducted, which is standard for most medications in this class.

A 2024 observational study published in NEJM using Danish and Norwegian registry data found that first-trimester GLP-1 agonist exposure was not associated with a significantly increased risk of major birth defects compared to unexposed controls, though the authors cautioned that sample sizes were limited and longer-term infant outcomes were not assessed. This is the strongest human-pregnancy dataset available, but it does not overturn the FDA contraindication, which is based on animal teratogenicity data.

Stop semaglutide before you try to conceive

Because semaglutide has a half-life of approximately one week and requires roughly five weeks to clear the body, the FDA label recommends stopping Ozempic at least two months before a planned pregnancy. This washout period allows concentrations to fall to negligible levels before conception.

For women using semaglutide off-label for PCOS-related weight management or insulin resistance, this timing is clinically significant. PCOS patients who are trying to conceive should not be on semaglutide, and those who are sexually active while on semaglutide should use reliable contraception.

Contraception requirements

No regulatory body has issued a formal contraception mandate for semaglutide the way one exists for isotretinoin under iPLEDGE, but the teratogenicity signal in animals and the two-month washout recommendation together make reliable contraception a clinical standard of care for any woman on semaglutide who is not actively trying to conceive. Barrier methods combined with hormonal contraception or a long-acting reversible contraceptive (IUD or implant) provide the most reliable protection. Note that semaglutide may slow gastric emptying in a way that could theoretically affect oral contraceptive absorption timing, though this effect has not been shown to be clinically significant at standard doses.

Lactation: the recommendation in plain terms

Stop Ozempic before breastfeeding begins, or do not start it while you are nursing. If you have a clinical need that cannot wait (for example, T2D that is not controlled by other agents), have a direct conversation with your prescriber about the risk-benefit balance for your specific situation. Stopping breastfeeding to resume Ozempic is a personal decision with its own health implications, and it should not be made under pressure or without full information.

Postpartum life stage: what you can do instead

If you have type 2 diabetes

Women with T2D who were using Ozempic for glycemic control before or during the pregnancy planning period have lactation-compatible alternatives:

• Insulin: The most studied agent in lactation. Insulin does not transfer into breast milk in clinically meaningful amounts and is considered compatible with breastfeeding.
• Metformin: LactMed lists metformin as probably compatible with breastfeeding based on multiple studies showing low milk transfer and no adverse infant effects. Infant exposure is estimated at less than 0.5% of the maternal weight-adjusted dose.
• Glyburide: Data exist but are more limited. Discuss with your provider.

SGLT-2 inhibitors and DPP-4 inhibitors do not have adequate lactation data either, so they are not automatically preferred alternatives.

If you are using Ozempic for weight loss only

For postpartum weight management in the absence of T2D, the evidence base for non-pharmacologic approaches is meaningful:

• Breastfeeding itself is associated with modestly greater postpartum weight loss compared to formula feeding. A meta-analysis of 14 studies found that breastfeeding was associated with an additional 0.38 kg of weight loss per month postpartum compared with non-breastfeeding.
• Caloric restriction paired with structured exercise beginning at 6 to 8 weeks postpartum is effective and safe in nursing women. A deficit of 500 kcal per day does not compromise milk volume or composition in well-nourished women.
• Orlistat: Minimal systemic absorption means negligible milk transfer, but gastrointestinal side effects make it poorly tolerated for many postpartum women.

Women with PCOS postpartum

PCOS-related insulin resistance does not disappear after delivery. For women who used semaglutide off-label to manage PCOS-related metabolic dysfunction, the postpartum period requires a recalibrated plan. Metformin is first-line for insulin resistance in PCOS and is compatible with breastfeeding. Inositol supplementation (myo-inositol 2 g twice daily) has some evidence in PCOS but is not FDA-approved. A 2020 Cochrane review found insufficient evidence to recommend inositol for PCOS outcomes beyond modest improvements in metabolic markers. Dietary changes that reduce glycemic load remain the foundation.

The evidence gap: what we are missing and why it matters

Women have been systematically excluded from clinical trials throughout the history of pharmacology. GLP-1 agonist trials are no exception. The SUSTAIN and STEP trial programs enrolled large numbers of participants, but lactating women were excluded from STEP 1 and all major semaglutide trials as a standard exclusion criterion. This means the weight-loss and safety data we do have cannot be applied to breastfeeding women.

A 2022 analysis in Obstetrics and Gynecology found that fewer than 5% of FDA drug approvals between 2000 and 2020 included lactation data adequate to calculate a reliable infant dose. Semaglutide is one of hundreds of drugs in this category.

The clinical consequence is that providers are making decisions in the dark, guided by molecular pharmacology reasoning and animal data rather than human evidence. Being honest about this gap is not an admission of failure. It is the only intellectually responsible position.

How hormonal changes postpartum interact with GLP-1 physiology

Postpartum hormonal physiology is distinct from any other life stage. Estrogen and progesterone drop precipitously after delivery. Prolactin rises to support milk production. Thyroid function fluctuates, and postpartum thyroiditis affects roughly 5% to 10% of women in the first year after delivery. Postpartum thyroiditis is more common in women with pre-existing autoimmune conditions and can cause transient hyperthyroidism followed by hypothyroidism.

GLP-1 receptor agonists have complex interactions with thyroid tissue. The Ozempic label carries a boxed warning about thyroid C-cell tumors based on rodent data, though human relevance remains unconfirmed. In a woman with postpartum thyroiditis who is already experiencing thyroid instability, adding a drug with a theoretical thyroid signal warrants extra caution, even if that signal has not been confirmed in humans.

Appetite and energy regulation also shift postpartum. GLP-1 suppresses appetite. In a nursing mother who already has elevated caloric needs (roughly 330 to 400 additional kcal per day for lactation), appetite suppression may contribute to inadequate caloric intake, which can reduce milk supply. No trials have studied semaglutide's effect on milk volume or composition, but this is a physiologically plausible concern.

Who this is right for, and who it is not

Not right for: most postpartum breastfeeding women

If you are actively breastfeeding and your reason for wanting Ozempic is weight loss, the current evidence does not support its use. The risk to your infant is unknown, the need for rapid pharmacologic weight loss postpartum is generally not urgent, and alternatives exist.

Not right for: women who are pregnant

Ozempic is contraindicated in pregnancy based on animal teratogenicity data. Stop it two months before trying to conceive.

A possible exception: severe, uncontrolled T2D

A small number of postpartum women with T2D may not achieve glycemic control on insulin and metformin alone. In those cases, the prescriber must weigh the risks of poorly controlled maternal diabetes (which carries its own risks for the breastfed infant via maternal health outcomes) against the unknown risk of semaglutide in milk. This is a decision that belongs in a shared clinical conversation, not a general recommendation.

Right for: non-lactating postpartum women with clinical indication

If you have stopped breastfeeding and have a clinical indication for semaglutide (T2D or BMI ≥30, or BMI ≥27 with a weight-related comorbidity under Wegovy's approved indication), resuming or starting semaglutide is clinically appropriate and not restricted by lactation concerns once nursing has stopped.